The Effect of Curcumin Supplementation on Pulse Wave Velocity in Patients with Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

Alidadi, Mona; Sahebkar, Amirhossein; Eslami, Saeid; Vakilian, Farveh; Jarahi, Lida; Alinezhad-Namaghi, Maryam; Arabi, Seyed Mostafa; Vakili, Saba; Tohidinezhad, Fariba; Nikooiyan, Yasaman; Norouzy, Abdolreza

doi:10.1007/978-3-030-64872-5_1

Cited by 24 publications

(16 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These effects may help improve arterial stiffness caused by inflammation and increased luminal pressure. A study conducted by Alidadi et al revealed that consuming 500 mg of curcumin every day for 12 weeks has beneficial effects on arterial stiffness and can control the weight of individuals with MetS [ 270 ]. After 12 weeks of curcumin administration, there was a statistically significant decrease in mean body weight in the control compared to the placebo group; however, body composition and other anthropometric parameters revealed no major changes.…”

Section: Managementmentioning

confidence: 99%

“…However, after 12 weeks of curcumin supplementation, a significant decrease in PWV was observed, with amelioration of aortic stiffness in MetS patients. Even after adjusting for confounding factors, including gender, age, change in physical activity, and energy intake by regression, the daily consumption of curcumin significantly lowered aortic PWV, relative to placebo [ 270 ]. Moreover, in terms of diabetes and dyslipidemia, fasting blood glucose did not improve in the group treated with curcumin, and lipid profiles remained unchanged.…”

Section: Managementmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic Syndrome: Updates on Pathophysiology and Management in 2021

Fahed

Aoun

Zerdan

et al. 2022

IJMS

708

366

View full text Add to dashboard Cite

Metabolic syndrome (MetS) forms a cluster of metabolic dysregulations including insulin resistance, atherogenic dyslipidemia, central obesity, and hypertension. The pathogenesis of MetS encompasses multiple genetic and acquired entities that fall under the umbrella of insulin resistance and chronic low-grade inflammation. If left untreated, MetS is significantly associated with an increased risk of developing diabetes and cardiovascular diseases (CVDs). Given that CVDs constitute by far the leading cause of morbidity and mortality worldwide, it has become essential to investigate the role played by MetS in this context to reduce the heavy burden of the disease. As such, and while MetS relatively constitutes a novel clinical entity, the extent of research about the disease has been exponentially growing in the past few decades. However, many aspects of this clinical entity are still not completely understood, and many questions remain unanswered to date. In this review, we provide a historical background and highlight the epidemiology of MetS. We also discuss the current and latest knowledge about the histopathology and pathophysiology of the disease. Finally, we summarize the most recent updates about the management and the prevention of this clinical syndrome.

show abstract

Section: Managementmentioning

confidence: 99%

Section: Managementmentioning

confidence: 99%

Metabolic Syndrome: Updates on Pathophysiology and Management in 2021

Fahed

Aoun

Zerdan

et al. 2022

IJMS

708

366

View full text Add to dashboard Cite

show abstract

“…All studies compared one to two CL forms of supplementation with placebo. Sixteen [41,42,45,49,54,55,[58][59][60][61][62][64][65][66]68,70,71], six [20,43,46,47,52,63,67,72], and three [48,56,57,69] studies involved patients with T2DM, MetS, and prediabetes, respectively, whereas three studies [44,50,51,53] involved a mix of these three patient types. The mean age range was 34.5-70.0 years and 34.2-69 years in the CL and placebo groups, respectively, whereas the mean BMI range 23.4-31.7 kg/m 2 and 22.8-31.9 kg/m 2 , respectively.…”

Section: Updated Meta-analysismentioning

confidence: 99%

“…CL preparation forms and outcomes. Regarding CL preparation forms, 11 [42,43,48,49,54,56,57,61,62,[70][71][72], 11 [20,[45][46][47]52,53,60,[63][64][65][66][67][68][69], and 7 Risk of bias of included RCTs. The overall risk of bias in 7 (25%) [43][44][45]48,49,52,72], 14 (50%) [41,42,46,47,50,51,[53][54][55][56][57][58][60][61][62]67,68], and 7 (25%) [20,…”

Section: Updated Meta-analysismentioning

confidence: 99%

Effects of turmeric (Curcuma longa) supplementation on glucose metabolism in diabetes mellitus and metabolic syndrome: An umbrella review and updated meta-analysis

Pathomwichaiwat,

Jinatongthai,

Prommasut

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Aims This study aims to comprehensively review the existing evidence and conduct analysis of updated randomized controlled trials (RCTs) of turmeric (Curcuma longa, CL) and its related bioactive compounds on glycemic and metabolic parameters in patients with type 2 diabetes (T2DM), prediabetes, and metabolic syndrome (MetS) together with a sub-group analysis of different CL preparation forms. Methods An umbrella review (UR) and updated systematic reviews and meta-analyses (SRMAs) were conducted to evaluate the effects of CL compared with a placebo/standard treatment in adult T2DM, prediabetes, and MetS. The MEDLINE, Embase, The Cochrane Central Register of Control Trials, and Scopus databases were searched from inception to September 2022. The primary efficacy outcomes were hemoglobin A1C (HbA1C) and fasting blood glucose (FBG). The corrected covered area (CCA) was used to assess overlap. Mean differences were pooled across individual RCTs using a random-effects model. Subgroup and sensitivity analyses were performed for various CL preparation forms. Results Fourteen SRMAs of 61 individual RCTs were included in the UR. The updated SRMA included 28 studies. The CCA was 11.54%, indicating high overlap across SRMAs. The updated SRMA revealed significant reduction in FBG and HbA1C with CL supplementation, obtaining a mean difference (95% confidence interval [CI]) of –8.129 (–12.175, –4.084) mg/dL and –0.134 (–0.304, –0.037) %, respectively. FBG and HbA1C levels decreased with all CL preparation forms as did other metabolic parameters levels. The results of the sensitivity and subgroup analyses were consistent with those of the main analysis. Conclusion CL supplementation can significantly reduce FBG and HbA1C levels and other metabolic parameters in T2DM and mitigate related conditions, including prediabetes and MetS. Trial registration PROSPERO (CRD42016042131).

show abstract

“…As such, middle-aged and older men and women taking curcumin for 8-12 wk did not lower arterial stiffness assessed by cfPWV. 34,35 Notably, a 12-wk curcumin intervention in middle-aged adults (n = 66, age 42.8 ± 6.3 yr) with metabolic syndrome lowered cfPWV by ∼1 m/sec, 36 which is equivalent to a ∼15% reduction in CVD risk. 16 Further, curcumin treatment in young adults (n = 22, age 26.2 ± 4.3 yr) lowered cfPWV after 12-wk but only in participants with a higher baseline arterial stiffness.…”

Section: Curcuminmentioning

confidence: 99%